Banchereau, Jacques F.,Zurawski, Gerard,Flamar, Anne-laure,Cobb, Amanda,Mead, Holly,Montes, Monica
申请号：
AU2012202953
公开号：
AU2012202953B2
申请日:
2012.05.21
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
#$%^&*AU2012202953B220140529.pdf#####ABSTRACT The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cy clin DI.
